it is marketed under the trade name tikosyn by pfizer and is available in the united states in capsules containing 125 250 and 500 g of dofetilide it is not available in europe or australia in the united states it is only available by mail order or through specially trained local pharmacies dofetilide is used for the maintenance of sinus rhythm in individuals prone to the occurrence of atrial fibrillation and flutter arrhythmias and for chemical cardioversion to sinus rhythm from atrial fibrillation and flutter based on the results of the danish investigations of arrhythmias and mortality on dofetilide diamond study dofetilide does not affect mortality in the treatment of patients post myocardial infarction with left ventricular dysfunction however it was shown to decrease all cause readmissions as well as chf related readmissions because of the results of the diamond study some physicians use dofetilide in the suppression of atrial fibrillation in individuals with lv dysfunction however use appears limited after initially receiving marketing approval in europe in 1999 pfizer voluntarily withdrew this approval in 2004 for commercial reasons and it is not registered in other first world countries it has clinical advantages over other class iii antiarrhythmics in chemical